

*Market Scope*<sup>®</sup>

# 2025 Nonexudative Retinal Disease Pharmaceuticals Market Report

Global Analysis for 2024 to 2030

**\$1.4B**

2025 MARKET  
FORECAST

**218**

COMPREHENSIVE  
PAGES

**19**

COMPETITOR  
PROFILES

**8**

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

AUTHOR  
Peter Downs

PUBLISHED  
October 2025

The “2025 Nonexudative Retinal Disease Pharmaceuticals Market Report” features updated disease estimates for geographic atrophy and other nonexudative retinal conditions and fresh forecasts for complement inhibitors, gene therapies, and other emerging treatment classes.

This year’s edition expands coverage of clinical-stage drug development programs and tracks progress in drug-delivery technologies designed to improve treatment durability. It also includes new survey data on US physician experience with complement inhibitors and updated insights into how doctors in the US and Western Europe view and plan to adopt gene therapy techniques.

## Market Scope

# 2025 Nonexudative Retinal Disease Pharmaceuticals Market Report


The “2025 Nonexudative Retinal Disease Pharmaceuticals Market Report” provides a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It evaluates complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and more—examining key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.

The report also includes detailed unit and dollar demand projections, product category market shares, and profiles of 19 leading competitors with insights into their strategies and outlooks.


### Coverage includes:

- **Disease overview and risk factors:** discussion of nonexudative retinal diseases, their causes, disease progression, and links to systemic health and lifestyle.
- **Diagnosis and treatment landscape:** examination of diagnostic technologies, patient management trends, and the growing role of pharmaceutical intervention.
- **Global retinal care environment:** overview of global retinal care delivery, patient access, specialist distribution, and treatment adoption trends.
- **Current therapies in the market:** analysis of approved pharmaceuticals and biologics, including market penetration, pricing dynamics, and competitive positioning.
- **Development pipeline:** review of investigational agents in development—complement inhibitors, gene therapies, sustained-release devices, and more—shaping the next generation of care.
- **Company profiles and preclinical activity:** profiles of companies developing or marketing therapies for nonexudative retinal disease, plus a listing of additional firms with preclinical programs.

**Nonexudative Retinal Disease Pharmaceuticals Revenue Share by Product Type**



**Global Nonexudative Retinal Disease Pharmaceutical Market by Company Share of Revenue**



Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

## How to Order

Order your “2025 Nonexudative Retinal Disease Pharmaceuticals Market Report” now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

**2025 Exudative Retinal Disease  
Pharmaceuticals Market Report**

**\$8,400**

*(Price includes a printable PDF and  
supplemental Excel file with all the  
tables and figures in the report)*



### SINGLE-USER LICENSE

**2025 Exudative Retinal Disease  
Pharmaceuticals Market Report**

**\$5,600**



Printed Copy

**\$250**



### ONE-YEAR SUBSCRIPTION

**Ophthalmic Market  
Perspectives Newsletter**

**\$1,750**



Monthly Paper Copies

**\$100**

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

## Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

